Resource Summary Report

Generated by dkNET on Aug 4, 2026

PE/Dazzle(TM) 594 anti-human CD3

RRID:AB_2563618
Type: Antibody

Proper Citation

BioLegend Cat# 300450, RRID:AB_2563618

Antibody Information

URL: http://antibodyregistry.org/AB_2563618

Proper Citation: BioLegend Cat# 300450, RRID:AB_2563618

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Dazzle(TM) 594 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_2563618

Vendor: BioLegend

Catalog Number: 300450

Alternative Catalog Numbers: 300449

Record Creation Time: 20250820T061733+0000

Record Last Update: 20250820T234303+0000

Ratings and Alerts

No rating or validation information has been found for PE/Dazzle(TM) 594 anti-human CD3.

No alerts have been found for PE/Dazzle(TM) 594 anti-human CD3.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Li H, et al. (2025) Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer cell, 43(4), 757.

Neuwirth T, et al. (2025) The polyamine-regulating enzyme SSAT1 impairs tissue regulatory T cell function in chronic cutaneous inflammation. Immunity, 58(3), 632.

Patel E, et al. (2024) XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies. Molecular cancer therapeutics, 23(4), 421.

Krausgruber T, et al. (2023) Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. Immunity, 56(2), 289.

Luoma AM, et al. (2022) Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell, 185(16), 2918.

Höfle J, et al. (2022) Engagement of TRAIL triggers degranulation and IFN? production in human natural killer cells. EMBO reports, 23(8), e54133.

Biermann J, et al. (2022) Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell, 185(14), 2591.

Krämer B, et al. (2021) Early IFN-? signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 54(11), 2650.

Luoma AM, et al. (2020) Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell, 182(3), 655.

De Domenico E, et al. (2020) Optimized workflow for single-cell transcriptomics on infectious diseases including COVID-19. STAR protocols, 1(3), 100233.

Schulte-Schrepping J, et al. (2020) Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell, 182(6), 1419.